Shares of United Natural Foods, Inc. (NASDAQ:UNFI) opened at $36.87, and ended -2.3% lower at $36.05. Nearly 0.92 million shares were traded by the close, lower than its average daily volume of 1.03 million shares.
United Natural Foods, Inc. (UNFI) Analyst Opinion
United Natural Foods, Inc. has a consensus hold rating from 19 Wall Street analysts, and the number of shares currently sold short amount to at least 11.29% of shares outstanding. The stock sank -12.82% last month and is down -24.46 this year. Wall Street is only getting neutral on the stock, with 4 of analysts who cover UNFI having a buy-equivalent rating. Analysts have placed a $40.92 price target on United Natural Foods, Inc., suggesting a 13.51% gain from recent close. It’s currently trading about -30.91% below its 52-week high.
United Natural Foods, Inc. Earnings Surprise
United Natural Foods, Inc. (UNFI) surprised the stock market in its last reported earnings when it earned $0.77 a piece versus the consensus-estimated $0.76. Its revenue totaled $2.42 billion up 5.69% from the previous quarter.
United Natural Foods, Inc. (NASDAQ:UNFI) Intraday View
This stock (UNFI) is ahead of its 52-week low with 22.08%. Its last month’s stock price volatility remained 2.59% which for the week stands at 4.68%. The share price has moved backward from its 20 days moving average, trading at a distance of -3.77% and stays -8.88% away from its 50 days moving average. Over the last five days, shares have managed 3.15% gains and now is down -16.34% since hitting its 200-day moving average of $43.13. United Natural Foods, Inc. (UNFI) has made its way to a 12-month decline of -22.19%.
Turning to Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), its shares were trading at $1.9 a retreat of $-0.05, on the trading floor. The stock, after opening at $2, touched a high of $2.02 before paring much of its gains. So far, analysts are sticking with their neutral recommendations with the consensus call at 2. Titan Pharmaceuticals, Inc. has 0 buy ratings, 0 holds and 0 sells even after the stock tumbled -70.31% from its high of $6.4 to a $42.41 million market value through last close.
Titan Pharmaceuticals, Inc. (TTNP) Consensus Price Target
The company’s consensus rating on Reuter’s scale remained unchanged from 2 to 2 during a month. Analysts set a 12-month price target of $8 a share. The target implies a 321.05% spike from where the shares are currently trading. Also, the current price highlights a discount of 321.05% to analysts’ high consensus price target.
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Intraday Trading
The counter witnessed a trading volume of 0.23 million shares versus an average volume of 0.15 million shares during last trading session. Its last month’s stock price volatility remained 13.76% which for the week approaches 9.1%. The lowest price the stock reached in the last trading day was $1.83 and compares with the $1.8 52-week low. The stock recovered 5.56% since its low point and has performed -52.5% year-to-date.